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1The main option in reducing the impact of influenza is
immunoprophylaxis with an inactivated vaccine, a pre-
ventive measure particularly recommended for groups
with a high risk of complications. Antiviral drugs repre-
sent another therapeutic chance to reduce deaths, com-
plications, duration of hospitalization and could play a
role in prevention of the infection by chemio-prophy-
lactic action and by reducing the viral shedding of the
infected patient. Two classes of antiviral agents have
been used to treat influenza, the M2 ion channel in-
hibitors (MI), that include Adamantane derivates and
have been used for more than 30 years [1, 2], and the
Neuraminidase inhibitors (NI), Zanamivir and Os-
eltamivir, available since the half of ninety [3, 4]. These
two classes of drugs target different viral proteins and
have different mechanisms of action on the replication
cycle of the virus. Amantadine inhibit virus replication
during the early stage of infection by blocking the ion
channel formed by the transmembrane domain of M2
protein [5, 6], and NI interrupt replication cycle by pre-
venting virus release [7]. MI drug resistant mutants are
present in about 30% of treated patients although Japan-
ese authors have reported that the frequency of resistant
viruses in children treated with Amantadine could be
high as 80% [8, 9]. Recent reports on the global preva-
lence of adamantine-resistant viruses indicate a signifi-
cant increase of drug resistance, from 1.8% during the
2001/02 influenza season to 12.3% during the 2003/04
season [10]. In USA, > 90% of the virus isolated during
the first months of 2005/06 showed amino acid muta-
tions known to be correlated with Adamantane resis-
tance. In contrast to Amantadane resistance, NI resis-
tance remains rare worldwide [11]. 
In South Europe the susceptibility profile of influenza
isolates is poorly investigated and the possible clinical
and epidemiological consequences are unclear. A sub-
set of the viruses isolated during the last five influenza
seasons (2000-2005) by CIRI-IV national network
were characterized, including sequence analysis for an-
tiviral susceptibility.
A total of 40 isolates were selected as representative of
viruses circulating during the 1999-2005 influenza sea-
sons: 5 were subtyped A/H1N1 and 35 were A/H3N2,
using primer-specific polymerase chain reaction
(PCR). No patients from whom viruses were isolated
were treated with MI or NI. The sequence analysis of
hemoagglutinin (HA), neuraminidase (NA) and matrix
(M) genes of the viral isolates were performed: reverse
transcription PCR (RT-PCR) and sequencing were per-
formed using primers specific for the HA, NA and M
gene segments, kindly supplied by Alan Hay, WHO In-
fluenza Centre, London, UK and BigDye Terminator
Cycle Sequencing Kit on an ABI PRISM 3100 DNA
Analyzer (Applied Biosystems). Amino acid substitu-
tions in position 26, 27, 30, 31, 34 in the M2 protein
and 119, 152, 274, 292, 294 in the NA gene were con-
sidered related to drug resistance [12, 13]. HA se-
quence was performed as, although such NA-inhibitors
act mainly on neuraminadase, viruses with HA substi-
tutions, that are usually selected first, reduce the sialic
acid-binding activity of the HA; the HA mutant be-
comes less dependent on the sialase activity of the NA,
whereas subsequent NA mutations render the virus ful-
ly resistant [14].
In Table I were reported the amino acid substitutions
observed in the collected viruses in the hydrophobic se-
quences in the trans-membrane region of the M2 pro-
tein. No strain isolated before 2004 showed amino acid
substitution related to Amantadine or Rimantadine re-
sistance, while 4 out of 24 (16.7%) viruses collected
during the 2004/05 season showed S31N substitution.
Interessangly, in the 4 S31N escape mutants, other mu-
tations at codon 21, 27 and 28 (D21G, V27T and V28I)
in the trans-membrane region were observed; in partic-
ular, substitution in position 27 was observed in Aman-
tadine or Rimantadine resistant viruses isolated in Asia
and America, but Valine was usually substituted with
Alanine (V27A) [10, 15].
The 4 escape mutants were A/H3N2 viruses collected
in the first weeks of the 2004/05 epidemic and the
above mentioned mutations were not present in the
A/H1N1 and A/H3N2 viruses isolated during the peak
and when the incidence decreased. The patients from
whom drug-resistant viruses were isolated were < 8
year children who lived in different areas of Genoa and
they did not appear epidemiologically correlated. The
hemagglutination inhibition (HI) test and HA-NA se-
quence analysis allowed to characterize the 4 viruses as
belonging to a distinct cluster very close to
A/H3N2/Panama/2007/99.
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The alarming increase in incidence of Amantadine-re-
sistant and Rimantadine-resistant influenza A viruses
over the past decade described in Asia and America
was not entirely observed in this Italian surveillance:
the drug-resistant virus proportion of 16.7% observed
during the 2004/05 season was similar than that regis-
tered in USA (15%) during the same season and very
much lower than that reported in China and Hong Kong
during the 2003/04 season (70 and 74%, respectively)
and in the U.S.A. during the 2005/06 season (92%).
The 4 drug resistant viruses present very peculiar epi-
demiological and virological figures: the early circula-
tion during the 2004/05 epidemic, the young age of the
infected patients and the belongings to a antigenic clus-
ter that circulated very rarely during the 2004/05 sea-
son. A/H3N2/California/7/04-like viruses, that pre-
dominated during the epidemic did not showed muta-
tion related to MI-resistance [16].
The effect of Adamantane use on epidemiological data
is very difficult to assess as data on Adamantine treat-
ment or exposure are available only in the U.S.A.,
where of the 92 patients from whom drug-resistant
viruses were isolated since 2004, only two (2%) were
known to have receive MI treatment before virus col-
lection [10]. Furthermore, MI are available in over-the-
counter formulations and do not need prescription in
China, Russia and some other countries [17, 18]. In
Italy the use of MI is very limited and no patients from
whom viruses were isolated were treated. MI-resistant
mutations could be occurred without the drug pressure
as reported by Bright [10]: he described A/H1N1 virus-
es, isolated in 1930’s (A/PR/8/34 and A/WSN/33), be-
fore these drugs were developed, presenting amino acid
substitution associated with resistance. 
More studies are needed to define the circulation of
MI-resistant viruses, the frequency with which they are
transmitted and their impact on effort to control in-
fluenza. This data are of fundamental importance in re-
lation to strategies for MI or combined MI-NI use in
case of epidemic or pandemic. On the other hand, no
virus showed amino acid mutations related to NI-resis-
tance: the lack of emergent resistance make them the
drug of choice for prophylactic or therapeutic purpose. 
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